Insomnia: Recent advances in pharmacological management

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


The medications currently approved for the treatment of insomnia include 9 benzodiazepine receptor agonist (BZRA) hypnotics and the selective melatonin receptor agonist ramelteon. The BZRA hypnotics include the newer nonbenzodiazepine agents as well as benzodiazepines; the nonbenzodiazepine hypnotics tend to have shorter half-lives and are better at targeting sedation exclusively during the nighttime. The development of modified-release formulations of BZRA hypnotics, such as Zolpidem extended-release, has been a key innovation. These formulations allow both rapid and sustained release of the medication and may reduce the risk of next-day effects. Ramelteon has been shown to improve sleep during the early portion of the sleep period. Investigational agents include alternate-delivery formulations of BZRA compounds, which may help treat nighttime awakenings.

Original languageEnglish (US)
Pages (from-to)266-271
Number of pages6
JournalDrug Benefit Trends
Issue number9
StatePublished - Oct 1 2009


  • Insomnia
  • Sleep disorders

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)


Dive into the research topics of 'Insomnia: Recent advances in pharmacological management'. Together they form a unique fingerprint.

Cite this